NOXXON Pharma AG
Edit

NOXXON Pharma AG

http://www.noxxon.com/
Tags:AlternativeBiopharmaBioTechBuildingCareDataDevelopmentManagementPlatform
NOXXON Pharma is a clinical-stage biopharmaceutical company whose core focus is on improving cancer treatment by targeting the tumor microenvironment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
Total raised: $66.339998M
Founded date: 1998

Investors 4

Funding Rounds 6

DateSeriesAmountInvestorsDeal News
29.12.2021-$19.183699...-marketscre...
30.04.2021-$1.449627M-marketscre...
06.08.2019-$1.1187M-biospace.c...
09.05.2017-$1.088626M-tvm-lifesc...
12.10.2010Series D$2.775599M-finsmes.co...
27.05.2010-$40.723747...-finsmes.co...

Mentions in press and media 37

DateTitleDescriptionCategoryAuthorSource
31.01.2022NOXXON ANN...Berlin, Germany - NOXXON Pharm...--marketscre...
29.12.2021NOXXON Pha...NOXXON SECURES €17 MILLION EXP...--marketscre...
15.12.2021NOXXON Pha...NOXXON TO PARTICIPATE IN BANKI...--marketscre...
15.12.2021NOXXON Pha...NOXXON ANNOUNCES RESULTS OF TH...--marketscre...
22.11.2021NOXXON: Ne...NOXXON: NEW PHASE 1/2 DATA ON ...--marketscre...
15.11.2021NOXXON Pha...NOXXON ANNOUNCES CONVOCATION O...--marketscre...
09.11.2021NOXXON to ...NOXXON TO PRESENT AT THE THIR...--marketscre...
03.11.2021NOXXON pro...NOXXON PROVIDES UPDATE ON TIMI...--marketscre...
27.10.2021Experience...EXPERIENCED FINANCIAL EXECUTIV...--marketscre...
19.10.2021NOXXON Pha...NOXXON ANNOUNCES PLANNED EXPAN...--marketscre...
Show more